Summary: Researchers have identified a promising drug target for Fragile X syndrome, the most common genetic cause of autism and intellectual disability. The study shows that loss of the FMR1 gene causes an abnormal, widespread increase of a synapse-localized protein called EPAC2 across multiple brain cell types.
In mouse models, blocking EPAC2—either genetically or with a small-molecule antagonist—restored disrupted brain circuit function and reversed core behavioral symptoms, including tactile hypersensitivity, social interaction deficits, and increased seizure susceptibility.
Key Facts
- The single-gene origin: Fragile X syndrome is caused by a mutation in the FMR1 gene that prevents production of a protein essential for normal brain development. The condition affects about 1 in 2,000 boys.
- EPAC2 identified: Using cell-type–specific RNA sequencing in Fmr1 knockout mice, researchers found that EPAC2 (encoded by Rapgef4) is abnormally elevated at synapses. EPAC2 is known to play a role in learning and memory.
- Rebalancing neural systems: Fragile X is associated with an imbalance between excitatory and inhibitory neurons. Although FMR1 loss alters these cell types in different ways, EPAC2 was consistently upregulated across both systems, making it a promising unified target.
- Brain specificity reduces systemic risk: EPAC2 is expressed almost exclusively in the brain, so drugs that target it are less likely to cause harmful effects in other organs.
- Relevance beyond early development: EPAC2 levels increase as the brain matures, suggesting that therapeutics aimed at EPAC2 could be effective for older children and adults, not only during a narrow early-development window.
Source: UCLA
UCLA Health researchers have pinpointed a potential therapeutic target for Fragile X syndrome, a leading monogenic cause of intellectual disability and autism.
Fragile X syndrome arises from a change in the FMR1 gene that stops production of a protein required for normal brain development. People with Fragile X frequently experience intellectual disability, attention and social interaction challenges, increased sensitivity to sensory input (such as sound and touch), and an elevated risk of seizures. Many individuals with Fragile X also meet diagnostic criteria for autism spectrum disorder.
Because Fragile X is caused by a single gene, it has long been seen as a strong candidate for targeted therapies, but clinical trials have yet to produce an effective treatment. Instead of attempting to replace the missing FMR1 protein directly, the UCLA-led team investigated downstream molecular consequences of FMR1 loss to find actionable targets.
Published in Neuron, the study used genetically engineered mice that lack the Fmr1 gene to model Fragile X. Cell-type–specific translatome profiling—sequencing mRNA being actively translated—revealed that Rapgef4 (EPAC2) was consistently upregulated at synapses. Because EPAC2 is synapse-localized and implicated in neuronal signaling and memory, it emerged as a high-priority candidate.
The researchers then blocked EPAC2 in Fragile X mice, using both genetic deletion and a selective EPAC2 antagonist. These interventions normalized cortical circuit activity and improved multiple behaviors linked to Fragile X, including tactile hypersensitivity, social deficits, and seizure vulnerability.
“EPAC2 stood out because it was consistently altered across multiple neuronal cell types in our analysis,” said lead author Dr. Anand Suresh, a postdoctoral fellow in the lab of Dr. Carlos Portera-Cailliau at UCLA. “When we inhibited EPAC2, either genetically or pharmacologically, we observed meaningful recovery in both circuit function and behavior.”
Importantly, EPAC2’s brain-enriched expression profile makes it an attractive therapeutic target from a safety perspective: drugs directed at EPAC2 are less likely to produce off-target effects in non-neural tissues. That specificity, together with its consistent dysregulation across excitatory and inhibitory neurons, addresses two critical hurdles in developing Fragile X treatments.
To identify EPAC2, the team separated two major cortical neuron classes—excitatory (Camk2a-expressing) and inhibitory (Pvalb-expressing)—and profiled their translating mRNAs in Fmr1 knockout mice. The data showed notable genotype-by-cell-type interactions: many signaling pathways were altered in opposite directions across the two cell types, highlighting the complexity of Fragile X pathology. Yet a small set of genes, including Rapgef4/EPAC2, were concordantly dysregulated in both neuronal classes.
The study also reports that EPAC2 levels rise gradually with brain maturation, indicating that EPAC2-targeted therapies could benefit older children, adolescents, and adults—not just infants—expanding the potential treatment window for people living with Fragile X.
Key Questions Answered:
A: Although gene-replacement is an appealing strategy, translating it into safe and effective human therapies has proven difficult. The UCLA team focused instead on downstream molecular changes caused by FMR1 loss. By targeting an overactive protein (EPAC2) that mediates circuit dysfunction, they were able to restore neural balance and behavior in mice without directly repairing the mutated gene.
A: EPAC2 meets two crucial criteria: uniform dysregulation and tissue specificity. It was one of the rare proteins elevated across both excitatory and inhibitory neurons in Fragile X models, and it is largely restricted to the brain. Those features increase the chance that an EPAC2-directed therapy could be both broadly effective and safe.
A: No. EPAC2 levels increase as the brain matures, so interventions that block EPAC2 may be effective outside a narrow early-development window. That raises the possibility of meaningful therapeutic benefit for older children, teens, and adults with Fragile X.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The original journal paper was reviewed in full.
- Additional context was added by editorial staff.
About this Fragile X syndrome research news
Author: Will Houston
Source: UCLA
Contact: Will Houston – UCLA
Image: Image credited to Neuroscience News
Original Research: Open access. “Translatome profiling reveals opposing alterations in inhibitory and excitatory neurons of Fragile X mice and identifies EPAC2 as a therapeutic target” by Anand Suresh et al., Neuron. DOI: 10.1016/j.neuron.2026.04.032
Abstract
Translatome profiling reveals opposing alterations in inhibitory and excitatory neurons of Fragile X mice and identifies EPAC2 as a therapeutic target
Fragile X syndrome (FXS), the leading monogenic cause of intellectual disability and autism, is thought to arise from an imbalance between excitation and inhibition (E/I) in cortical circuits. In this study, researchers used cell-type–specific mRNA sequencing to profile molecular changes in cortical excitatory (Camk2a) and inhibitory (Pvalb) neurons of Fmr1 knockout mice, integrating those results with circuit and behavioral data to prioritize therapeutic targets.
They observed significant genotype-by-cell-type interactions in differential gene expression, and many signaling pathways were altered in opposite directions across the two neuron classes. Among 184 genes concordantly dysregulated in both cell types, Rapgef4 (EPAC2) was uniquely notable: it was upregulated in Fmr1 knockout mice, is a known target of the fragile X protein FMRP, is enriched in brain tissue, and is associated with neurodevelopmental disorders.
Treating Fmr1 knockout mice with a selective EPAC2 antagonist restored cortical circuit function and improved multiple behavioral phenotypes. These results support considering EPAC2 as a potential therapeutic target for Fragile X syndrome.